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Background and Objectives
Preliminary data on the use of autologous stem cell transplantation (ASCT) as a sal-
vage therapy for peripheral T-cell lymphoma (PTCL) indicate that the results are simi-
lar to those obtained in aggressive B-cell lymphomas. The aim of our study was to
analyze outcomes of a large series of patients with PTCL with a prolonged follow-up
who received ASCT as salvage therapy. 
Design and Methods
Between 1990 and 2004, 123 patients in this situation were registered in the GELTA-
MO database. The median age at transplantation was 43.5 years; in 91% of patients
the disease was chemosensitive. 
Results
Seventy-three percent of the patients achieved complete remission, 11% partial
remission and the procedure failed in 16%. At a median follow-up of 61 months, the
5-year overall and progression-free survival rates were 45% and 34%, respectively. The
presence of more than one factor of the adjusted International Prognostic Index (a-
IPI) and a high β2-microglobulin at transplantation were identified as adverse prognos-
tic factors for both overall and progression-free survival and allowed the population to
be stratified into three distinct risk groups. 
Interpretation and Conclusions
Our data show that approximately one third of patients with PTCL in the salvage set-
ting may enjoy prolonged survival following ASCT, provided they are transplanted in a
chemosensitive disease state. The a-IPI and β2-microglobulin level predict the out-
come after ASCT in relapsing/refractory PTCL.
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β-2-microglobulin, autologous stem cell transplantation.
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ABSTRACT
Peripheral T-cell lymphoma (PTCL) is an heteroge-neous group of lymphomas constituting the largestgroup of adult T-cell non-Hodgkin’s lymphomas.1
According to the WHO classification, PTCL account for
approximately 10% of aggressive lymphomas, exclud-
ing cutaneous, lymphoblastic and human T-cell
leukemia/lymphoma.2 Unfortunately, there is little
information concerning these heterogeneous entities,
mainly due to their relatively low frequency and
because they have usually been assessed as part of larg-
er clinical studies on aggressive B-cell lymphomas. The
T-cell immunophenotype is almost unanimously
accepted as conferring a poor prognosis:3-6 although in
some reports this poor prognosis has been explained by
a greater distribution of unfavorable prognostic factors,7
the T-cell immunophenotype was considered as an
independent unfavorable prognostic factor in most rele-
vant series to date.5,8 The 5-year survival of patients
with most T-cell lymphomas is in the range of 20-40%,
which is lower than that of patients with the correspon-
ding aggressive B-cell lymphomas.3
Having established that high-dose chemotherapy
(HDC) with autologous stem cell rescue (ASCT) is cur-
rently the best available salvage therapy for patients
with aggressive chemosensitive lymphomas,9 it is logi-
cal to review whether this therapy offers benefits to
patients with the corresponding aggressive T-cell lym-
phomas. Indeed, the majority of retrospective series
showed a similar outcome between aggressive B- and T-
cell lymphomas after ASCT10-12 in the same setting,
although the studies generally involved a small number
of patients and a short follow-up period. Furthermore,
little or no relevant information is available regarding
prognostic factors in order to define which patients
might benefit from this therapeutic modality and which
will not.
In the present study, we analyze our experience with
a large group of PTCL patients observed over a pro-
longed period. A major goal of our study was to inves-
tigate the importance of clinical covariates in order to
obtain relevant pre-transplant prognostic information. 
Design and Methods
Patients 
Between 1990 and 2004, 123 patients were included
in the GEL/TAMO registry with a diagnosis of PTCL
according to the REAL or WHO classifications.2,13 These
patients were eligible to receive HDC/ASCT, if they had
PTCL, excluding lymphoblastic or cutaneous lym-
phoma, which had relapsed or if they had failed to
achieve complete remission after induction treatment.
Patients with severe concomitant medical or psychiatric
illnesses, central nervous system involvement or who
were human immunodeficiency virus seropositive,
were not eligible for this therapy. Other criteria for inel-
igibility included bilirubin levels above 1.5 mg/dL, a car-
diac ejection fraction less than 50% and pulmonary
function test and diffusing lung capacity less than 50%
of predicted values. The pathologist in each center
established the histological diagnosis. Those cases with
difficult diagnostic features were referred to expert
hematopathologists following the recommendations of
the group. The histological subtypes were as follows:
57% PTCL unspecified (PTCL-u) (n=70), 25% anaplas-
tic large T-cell lymphoma (n=31), 6% lymphoepithe-
lioid T-cell lymphoma (n=7), 8% angioimmunoblastic
T-cell lymphoma (n=10), 2% hepatosplenic γ/δ T-cell
lymphoma (n=2), 2% subcutaneous panniculitis-like T-
cell lymphoma (n=2) and 1% intestinal T-cell lym-
phoma (n=1). The disease stage was evaluated accord-
ing to the Ann Arbor staging system and patients were
staged according to standard procedures following
physical examination, blood and serum assays, chest X-
rays, and computed tomography of the neck, chest,
abdomen and pelvis. Bone marrow aspirates and biop-
sies were obtained prior to HDC, and other staging pro-
cedures were performed at diagnosis to fully determine
the pretransplant state. Standard variables of the adjust-
ed International Prognostic Index (a-IPI) (lactate dehy-
drogenase [LDH], performance status and Ann Arbor
stage)7 and other variables of known prognostic impor-
tance in this type of lymphomas were evaluated, such
as M.D. Anderson tumor score (Ann Arbor stage, LDH,
β2-microglobulin, B-symptoms and bulky disease) and
the Prognostic Index for PTCL (PIT) (age, LDH, bone
marrow involvement and performance status).14,15 The
clinical characteristics of the patients at diagnosis and at
the moment of transplantation are reported in Table 1.
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Table 1. Clinical characteristics of patients at diagnosis and at
transplantation.
Variable At diagnosis At transplantation
Age 43,5 (14-72)
Sex (male/female) 78 (63%)/45 (37%)
Ann Arbor Stage III-IV 89 (72%) 43 (35%)
B-symptoms 53 (43%) 11 (9%)
>1 extranodal sites 30 (25%) 7 (6%)
BM involvement 27 (22%) 12 (10%)
Bulky disease 30 (25%) 3 (2%)
ECOG > 1 37 (31%) 9 (7%)
High LDH 54 (47%) 22 (18%)
High β2M 31 (38%) 36 (41%)
Adjusted IPI 2-3 54 (47%) 20 (16%)
Tumor score 3-5 47 (45%) 11 (9%)
Pretransplant regimens
CHOP 74 (60%)
Others anthracycline-based 49 (40%)
Treatment lines pretransplant
One line 54 (44%)
Two lines 63 (51%)
Three lines 6 (5%)
Treatment plan
The pretransplant regimes followed were not uni-
form, but they were mainly based on anthracycline-
containing regimes (Table 1). The preparative regimes
and other transplant-related factors are presented in
Table 2. Of the 123 patients, 57 patients received the
BEAM regime (46%); 34 BEAC (28%); 13 cyclophos-
phamide/total body irradiation (11%); and the remain-
ing 19 other regimes (15%). The source of stem cells
was mobilized peripheral blood (PB) in 89 patients
(72%), bone marrow in 27 (22%) and from both in 7
patients (6%). Among the 96 patients who received PB
stem cells, the stem cells were mobilized with granulo-
cyte colony-stimulating factor (G-CSF) in 34 (35%),
with G-CSF and chemotherapy in 57 (59%), and with
chemotherapy alone in five cases.
Response and follow-up criteria
The response to therapy was evaluated by the inves-
tigator responsible in each center at 1, 3 and 6 months
post-ransplantation and every 6 months thereafter.
Evaluations were carried out following standard guide-
lines16 and included physical examination, complete
blood counts, serum biochemistry, bone marrow aspira-
tion and biopsy, and radiological studies as mentioned
above. A complete response (CR) was defined as the
disappearance of all clinical evidence of lymphoma for a
minimum of 4 weeks, with no persisting disease related
symptoms. Prior to transplantation, a complete restag-
ing was performed in all patients. A partial response
(PR) was defined as a decrease greater than 50% in the
sum of the products of the two longest diameters of all
measurable lesions for at least 4 weeks and non-meas-
urable lesions had to decrease by at least 50%. In this
category no increase in lesion size and no new lesions
were tolerated. Progressive disease (PD) was defined as
any increase greater than 25% in the sum of the diame-
ter of any measurable lesions or the appearance of new
lesions. Stable disease (SD) was considered as any con-
dition intermediate between PR and PD. Transplant-
related mortality (TRM) was defined as death within
100 days after HDC/ASCT that was unrelated to the
disease, relapse or progression. Toxic mortality was
considered at any time if it was related to the procedure.
Statistical methods
Overall survival (OS) and progression-free survival
(PFS) were measured from the date of transplantation
and were estimated according to the Kaplan-Meier
method.17 Comparisons among those variables of inter-
est were performed by the log-rank test.18 Multivariate
analysis with the variables that proved to be significant
in univariate analysis was performed according to the
Cox proportional hazard regression model.19 All p-val-
ues reported were two-sided and statistical significance
was defined at p<0.05. 
ASCT in salvage treatment of PTCL
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Figure 1. Overall and progression-free survival.
Table 2. Transplant-related factors.
Median months to transplant (range) 12 (3-215)
Disease status
First PR 44 (36%)
Second or more CR 44 (36%)
Second or more PR 20 (16%)
Refractory 11 (9%)
Non-treated relapse 4 (3%)
Conditioning regimens
BEAM 57 (46%)
BEAC 34 (28%)
Cy plus TBI 13 (11%)
CVB 12 (10%)
Others 7 (6%)
Stem cell source
BM 89 (72%)
PB 27 (22%)
BM plus PB 7 (6%)
Median aphereses (range) 2 (1-7)
Mobilization growth factor 91/96 (95%)
Purging 5 (4%)
Cytokines postransplant
G-CSF 82 (67%)
GM-CSF 6 (5%)
None 34 (28%)
Treatment-related mortality 5 (4%)
Engraftment 118/118 (100%)
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Results
Outcome
Response to transplantation was as follows: 87 of
the 119 (73%) patients in whom response could be
assessed achieved a CR, 13 a PR (11%) and the trans-
plant failed to produce benefits in 19 patients (16%)
who had SD or PD. The post-transplantation response
was not evaluated in four patients who died of trans-
plant-related causes: these patients were excluded
from PFS and disease-free survival (DFS) analyses.
After a median follow-up for the surviving patients of
61 months (range, 0-182), 57 (46%) were still alive.
Indeed, the OS at 5 years was 45% (95% CI; 36% to
55%) while the PFS was 34% (95% CI; 25% to 44%)
(Figure 1). Moreover, the DFS at 5 years for complete
responders was 47% (95% CI; 35% to 58%). Most of
the patients who died did so due to progression of the
disease (n=53), although three patients died of a sec-
ond neoplasia (malignancies in the lung, ovarian and
uterus). No cases of myelodysplastic syndromes were
observed during this follow-up period. The transplant-
related mortality was 4%, with two cases of severe
bleeding and three cases of fatal pneumonia.  
Prognostic factors for OS and PFS
The univariate analysis of prognostic factors that
might influence the OS and PFS is presented in Table
3. When we analyzed the influence of the pre-trans-
plant status of the disease on the outcome, we found
no differences between patients in second or subse-
quent CR (OS and PFS of 57% and 35%, respectively)
or those transplanted in the first PR (OS and PFS of
50% and 47%, respectively). However, the outcome
was significantly worse for those patients transplanted
in the second or subsequent PR (OS and PFS of 33%
and 23%, respectively) and those patients transplanted
in the refractory state of the disease (OS and PFS of 9%
and 10%).  
We also identified the following factors at transplant
that were associated with a poor OS (Table 3): more
than one point in the ECOG performance status score,
presence of B symptoms, more than one extranodal site
of disease, high LDH and high β2-microglobulin.
Among the prognostic systems analyzed, patients fared
significantly worse when they had, at the time of trans-
plantation, more than one factor of the a-IPI; more than
two factors of the MD Anderson Tumor Score, or more
than one factor of the PIT. Similarly, with respect to the
PFS the factors associated with a poor outcome were
the same as those that influenced OS with the excep-
tion of the presence of more than one extranodal site of
disease and more than one point of the ECOG perform-
ance status score, which proved not to be significant
factors. The aforementioned prognostic scores also
influenced the PFS, as shown in Table 3. 
Interestingly, patients who received radiotherapy
after their transplant (n=17) had a better OS and PFS
than patients who did not receive this consolidation
therapy. However, this is a retrospective finding that
should be confirmed in a prospective clinical trial, as
there was no homogeneous protocol to define when
radiotherapy should be administered post-transplanta-
tion. Among these patients, most had a bulky disease
at diagnosis (11 of 17) and all but one received first-line
consolidation (9 cases of PR and 1 with treatment fail-
ure) with HDC/ASCT followed by post-transplanta-
tion involved-field radiotherapy.
The group of patients with anaplastic T-cell lym-
phoma was analyzed separately since this group of
patients has a more favorable prognosis if the tumor
cells express the ALK tyrosine kinase. Unfortunately,
information regarding this marker was not available
for most of our patients. Nevertheless, we did not find
any differences in response rate, OS or PFS between
patients with anaplastic T-cell lymphoma and those
with the other subtypes. In fact, the CR rate after
transplant was 68% for the anaplastic group compared
to 72% for the other non-anaplastic group. Similarly,
the OS of both groups were 37% vs 48% (p=0.59), and
the corresponding PFS were 29% and 36% (p=0.76),
respectively.
Multivariate analysis
Following a multivariate analysis (Table 4), three fac-
tors emerged that provided significant independent
information regarding the OS: more than one adverse
factor of the a-IPI, a high β2-microglobulin level and
more than one extranodal site of disease. In the case of
PFS only β2-microglobulin remained independent.
Thus, taking into account the clinical factors that were
associated with both OS and PFS (β2-microglobulin
and a-IPI, excluding more than one extranodal site)
(Table 3), we analyzed the population with informa-
tion regarding these two variables (n=88). As shown in
Figure 2, this population could be divided into three
distinct prognostic groups by this two widely used
variables. Hence, patients with no pretransplant
adverse factors (52% of the population) had an OS and
PFS at 5 years of 60% and 43%, respectively. However,
among patients who displayed one adverse factor
(39% of the population), OS was 28% and PFS 24%.
Notably, the patients in whom both factors were
recorded pretransplant (9%) died of their disease. As
all of them were transplanted as a first line therapy (six
cases of 1st PR and two cases of 1st PD), these variables
could be helpful for identifying patients whose disease
state is refractory to both conventional and high-dose
chemotherapy.
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Discussion
The results obtained with ASCT as a salvage therapy
and with a long follow-up confirm preliminary data
obtained both by ourselves and others.10-12,20-22 Indeed,
the current report of 123 patients with a prolonged
median observation time of 61 months confirms our
previously published results involving 78 patients trans-
planted in the context of salvage therapy. In that series
of patients, we reported an OS and PFS of 45% and
39%, respectively, after 37 months of follow-up.22 No
differences in outcome can be seen when comparing
these results with those obtained in patients with
aggressive B-cell lymphomas.23 Similarly, a 58% OS and
48% PFS was reported in a study of 40 patients, 50% of
ASCT in salvage treatment of PTCL
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Table 3. Univariate analysis of prognostic factors at ASCT that influenced survival
Parameter N. OS at 5 years (95% CI) p N. PFS at 5 years (95% CI) p
Status at transplant 0.003 0.012
Second or more CR 44 57% (40-73) 44 35% (19-51)
First PR 44 50% (33-66) 41 47% (32-63)
Second or more PR 20 33% (8-58) 20 23% (4-42)
First SD or PD 8 12% (0-35) 7 14% (0-40)
Second or more SD or PD 3 0% 3 0%
Non treated relapse 4 37% (0-94) 4 0%
ECOG PS <0.001 0.079
0 or 1 114 49% (38-59) 112 36% (26-46)
2 to 4 9 11% (0-31) 7 14% (0-40)
Ann Arbor stage 0.077 0.07
I or II 80 53% (41-65) 79 38% (26-50)
III or IV 43 31% (16-47) 40 27% (13-41)
B symptoms 0.006 0.034
No 112 48% (37-58) 109 36% (26-45)
Yes 11 20% (0-46) 10 20% (0-45)
N. of extranodal sites 0.009
0 or 1 116 48% (38-58) 113 35% (25-44) 0.7
More than 1 7 14% (0-40) 6 33% (0-71)
BM involvement 0.93 0.7
Not involved 111 46% (36-57) 107 33% (23-43)
Involved 12 42% (14-70) 12 42% (14-70)
Bulky disease 0.4 0.95
No 120 45% (35-55) 116 34 (25-44)
Yes 3 67% (13-100) 3 33 (0-87)
LDH <0.001 0.034
Normal 101 50% (39-61) 100 36% (25-46)
High 22 24% (6-42) 19 26% (6-46)
β2-microglobulin <0.001 0.002
Normal 52 58% (43-73) 50 44% (29-58)
High 36 17% (3-32) 34 15% (2-28)
a-IPI <0.001 0.001
0 or 1 103 53% (42-64) n=123 102 38% (28-48)
More than 1 20 11% (0-24 ) 17 12% (0-27)
TS <0.001 <0.001
0 to 2 108 50% (39-60) 105 37% (27-47)
3 to 5 11 9% (0-26) 10 10% (0-29)
PIT <0.001 0.044
0 or 1 109 48% (38-59) 107 35% (26-45)
More than 1 11 18% (0-41) 9 22% (0-49)
RT post-ASCT 0.020 0.005
Yes 17 69% (47-92) 17 63% (39-87)
No 106 41% (30-52) 102 29% (20-39)
CR: complete response; PR: partial response; PD: progressive disease; ECOG PS: Eastern cooperative group performance status; BM: bone marrow;
a-IPI: adjusted-International Prognostic Index; TS: MD Anderson tumor score; PIT: prognostic index for peripheral T-cell lymphoma;
RT post-ASCT: radiotherapy after autologous stem cell transplantation. 
whom had PTCL-u.12 Moreover, in another study of 21
patients who underwent ASCT as salvage therapy for
relapsing and refractory disease, the 4-year OS rate was
34%.11 However, most reported series involve a small
number of patients and have a short follow-up; our
series of 123 patients with a median follow-up of more
than 5 years enables more meaningful conclusions to be
drawn.
Interestingly, we do not observe significant differ-
ences in the outcome between patients with anaplastic
T-cell lymphoma and PTCL-u when ASCT is used in
the salvage setting. Patients with anaplastic T-cell lym-
phoma expressing ALK have been shown to display
very favorable responses when treated with ASCT,
either as a front-line therapy or as salvage therapy.8,24-26
Thus, the fact that we could not find differences
between this group of patients and the rest of the
patients may indicate that ASCT overcomes the unfa-
vorable prognosis of the non-anaplastic group in the sal-
vage setting or alternatively, that most of the anaplastic
T-cell lymphoma patients in our population do not
express ALK. Unfortunately, data regarding the ALK
marker were not available for this group of patients.
Nevertheless, how anaplastic T-cell lymphomas that
express ALK and those that do not express ALK respond
to ASCT should be specifically addressed, to determine
whether they behave similarly to other subtypes of
PTCL in the salvage setting.
In our multivariate analysis, only single variables
emerged as significant factors that influenced OS and
PFS at the univariate level. In fact, patients who had
more than one adverse factor of the a-IPI pre-transplan-
tation and elevated β2-microglobulin responded poorly
to this therapeutic modality. The IPI serves to classify
patients with aggressive lymphomas into different risk
groups7 and indeed, it has also been shown to have
prognostic value for patients with PTCL.5,27 On the other
hand, elevated β2-microglobulin is known to be an
adverse prognostic factor in lymphoproliferative dis-
eases, being directly related to malignant tumor bur-
den28 but also maintains its adverse prognostic role
when other causes, such as renal impairment, are the
origin of the raised levels.14 Although this factor is not
included in the IPI, there is strong evidence of its inde-
pendent prognostic value in aggressive non-Hodgkin
lymphomas.14
We, therefore, reasoned that these two variables
might be useful to divide the population into different
groups, enabling us to predict the benefit of ASCT to
patients prior to performing the transplant. In fact, of
the 88 informative cases, 46 patients (52%) did not have
either of these two factors at the time of transplantation
and remarkably these patients had a 60% probability of
being alive 5 years after transplantation. This figure con-
trasts with the 28% probability of survival for the pop-
ulation that had one of these factors at the time of trans-
plantation. Furthermore, none of the 8% of the popula-
tion that had both factors at transplantation were alive
after 5 years. We consider that if these results are con-
J. Rodrìguez et al. 
| 1072 | haematologica/the hematology journal | 2007; 92(08)
Table 4. Multivariate analysis of prognostic factors influencing the
OS and PFS.
Overall survival Progression-free
(n=86) survival (n=84)
Parameter p RR (exp. B)95% CI p RR (exp. B) 95% CI
a-IPI > 1 0.017 2.41 1.17-4.94 0.11 1.82 0.87-3.81
High B2M <0.001 3.07 1.68-5.59 0.008 2.08 1.21-3.57
>1 extranodal site <0.001 8.02 2.78-23.1 − − −
B-symptoms 0.36 1.88 0.48-7.29 0.91 1.08 0.31-3.80
High LDH 0.28 0.47 0.12-1.83 0.33 0.53 0.15-1.92
TS > 2 0.79 0.79 0.13-4.69 0.28 2.85 0.42-19.18
PIT > 1 0.94 1.06 0.26-4.27 0.62 0.69 0.16-3.00
RT post-ASCT 0.13 0.44 0.15-1.26 0.07 0.41 0.15-1.08
Status at 0.95 − − 0.64 − −
transplant
ECOG PS > 1 0.68 1.50 0.21-10.48 − − −
RR: relative risk; CI: confidence interval; a-IPI: adjusted-International
Prognostic Index; β2M: β2-microglobulin; LDH: lactate dehydrogenase;
TS: tumor score; PIT: Prognostic Index for PTCL; ECOG PS: Eastern
Cooperative Oncology Group Performance Status. 
Figure 2. OS and PFS at 5 years according to the pre-transplanta-
tion a-IPI and β2-microglobulin status.
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firmed in an independent population, these two vari-
ables could prove to be reliable and user-friendly prog-
nostic indicator. Moreover, the system allowed us to
identify a small group of patients prior to transplanta-
tion who did not benefit from this procedure, in addi-
tion to the well-known chemoresistant cases. In fact,
new, experimental treatments should be evaluated for
salvage therapy of patients who are not chemosensitive
or who display both of these adverse factors. Among
such innovative approaches, non-myeloablative allo-
geneic hematopoietic transplantation has been tested.
Although this therapy has produced excellent prelimi-
nary results, these must be confirmed.29 New drugs,
such as histone deacetylase inhibitors (HDAI), borte-
zomib and rapamycin analogs, as well as monoclonal
antibodies that specifically target T-cell markers, are
also being tested.30-33 Indeed, given that adriamycin
offers little benefit to patients with T-cell lymphomas,34
the search should continue for drugs that are active
against T-cell lymphomas and that provide a more spe-
cific approach to treat this group of lymphomas. 
Our data confirm that the results with ASCT in both
aggressive T- and B-cell lymphomas are similar in the
relapse setting over a long observation period.
Therefore, it is logical to consider that front-line ASCT
consolidation of poor prognosis PTCL might improve
the outcome of this condition. Given the relatively low
frequency of PTCL, prospective studies and specifically
randomized studies are unlikely to be feasible outside of
an international setting, although preliminary results of
some studies have been presented.35-40 Many questions
urgently need to be answered. For instance, the biologi-
cal, prognostic and therapeutic implications of data
from tissue arrays and genomic cluster analysis of the
different so-called PTCL must be addressed, as has been
done for aggressive B-cell lymphomas. 
This task will be hampered by the fact that PTCL
comprise a heterogeneous group of rare entities that
probably have major differences. 
In conclusion, our data show that approximately one
third of patients with PTCL treated with ASCT in the
salvage setting may enjoy a prolonged survival, provid-
ed they are transplanted in a chemosensitive disease
state. The use of a-IPI and β2-microglobulin pre-trans-
plantation enables us to divide the population into three
very distinct prognostic groups, thus providing relevant
information that may aid therapeutic decisions. In fact,
patients in a refractory state pre-transplantation or who
have the two adverse factors considered do not appear
to benefit from ASCT, indicating that such patients
need innovative treatment. Finally, taking into account
the dismal prognosis of these patients when given con-
ventional chemotherapy alone as a front-line treatment,
these results in the salvage setting suggest that consoli-
dation with ASCT as a front-line therapy should be test-
ed.  
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